CD274 and cardiotoxicity: Compared with chemotherapy, patients receiving PD-1/PD-L1 inhibitors combined with chemotherapy had a significant higher risk of all-grade (OR=1.53, 95%CI 1.18-1.99, <i>P=</i>0.001) and grade 3-5 cardiotoxicity (OR=1.63, 95%CI 1.11-2.39, <i>P=</i>0.01) cardiotoxicity, especially patients with non-small cell lung cancer (NSCLC) [all-grade cardiotoxicity (OR=1.97, 95%CI 1.14-3.41, <i>P=</i>0.02) and grade 3-5 cardiotoxicity (OR=2.15, 95%CI 1.08-4.27, <i>P=</i>0.03)].